ATAI_OUT_1 [2025-04-02 17:43:30 -0400] 2815 Bytes | 759 tokens | Cum: 759 tkns (9.49% of 8k)
==========================================================================

You're the expert here today. So, I pulled together a bunch of data for you to look over real fast. I'm looking at high-performance stocks today and ATAI Life Sciences (ATAI) hit my radar screen, up to 1.47 from a prev close of 1.24 Do you think its got more juice or is it lacking potential? It's 5:43:29 PM on Wed Apr 02, 2025 -0400 and I have to decide: buy or sell!

--- COMPANY PROFILE ---
Company: ATAI Life Sciences (ATAI)
IPO: 2021-06-18 (3 Years Ago)
Market Cap: $269,716,609
Shares Outstanding: 198,310,000
Industry: PHARMACEUTICAL PREPARATIONS
Exchange: XNAS
Description: ATAI Life Sciences NV is a clinical-stage biopharmaceutical company on a mission to develop effective mental health treatments to transform patient outcomes. The company's pipeline of psychedelic-based therapies includes VLS-01 (buccal film DMT) for treatment-resistant depression (TRD) and EMP-01 (oral R-MDMA) for social anxiety disorder. It is also advancing a drug discovery program to identify novel, non-hallucinogenic 5-HT2AR agonists for TRD.

Here's the first list of news for ATAI Life Sciences:

C1 - Today 03:35PM - Is Atai Life Sciences (ATAI) the Best German Stock to Buy According to Hedge Funds?
C2 - Mar-22-25 10:30AM - Psychedelic: Exclusive talk with biotech company Clearmind Medicine
C3 - Mar-21-25 11:50AM - Psychedelic: atai Life Sciences, NRx report quarterly results
C4 - Mar-17-25 08:00AM - atai Life Sciences Reports Fourth Quarter and Full Year 2024 Financial Results and Recent Corporate Highlights
C5 - Mar-14-25 11:40AM - Psychedelic: atai reports dosing of first patient in Phase 2 VLS-01 trial
C6 - Mar-11-25 07:00AM - atai Life Sciences Announces First Patient Dosed in Elumina, the Phase 2 Clinical Trial of VLS-01 for Treatment-Resistant Depression
C7 - Mar-05-25 07:00AM - atai Life Sciences Announces Completion of Enrollment in Phase 2b Clinical Trial Evaluating BPL-003 for Treatment-Resistant Depression
C8 - Mar-01-25 11:08AM - Atai Life Sciences N.V. (ATAI): Among the Best Psychedelic Stocks to Buy in 2025

ONLY 3 RULES for AI:
==============
1) I am a document retrieval system. You are the analyst-investigator.
2) You can request items from my lists to get more info on ATAI Life Sciences (ATAI)
3) AFTER requesting and reading News and SEC filings you'll write a summary, set a score, high price target and headline.
Now, your response should be only 2 or 3 chars. You can say ex., C1, C2, etc., or NEX
The NEX command delivers the NEXt list of News/SEC/Metrics
There are several more lists that use our unified document retrieval system in subsequent prompts.
Your predictons will be compared to reality to rate your accuracy. Try to predict accurately. GOOD LUCK!
Please request a document, read, summarize and score. Say something like "C1".

ATAI_OUT_3 [2025-04-02 17:43:36 -0400] 1103 Bytes | 325 tokens | Cum: 1086 tkns (13.58% of 8k)
==========================================================================

Showing C4 (chunk 1 of 10): C4:
**atai Life Sciences Reports Fourth Quarter and Full Year 2024 Financial Results and Recent Corporate Highlights**
Date: Mar-17-25 08:00AM
Source: (GlobeNewswire)
URL: https://www.globenewswire.com/news-release/2025/03/17/3043651/0/en/atai-Life-Sciences-Reports-Fourth-Quarter-and-Full-Year-2024-Financial-Results-and-Recent-Corporate-Highlights.html

March 17, 2025 08:00 ET| Source:atai Life Sciencesatai Life Sciences

- Dosed the first patient in the Phase 2 Elumina trial of VLS-01 (buccal film DMT) for patients with treatment-resistant depression; topline data anticipated in Q1’26

- Initiated a Phase 2 clinical trial of EMP-01 (oral R-MDMA) for patients with social anxiety disorder; topline data anticipated in Q1’26

- Beckley Psytech completed enrollment in the Phase 2b study of BPL-003 (intranasal mebufotenin benzoate) in patients with treatment-resistant depression; topline data

--> You can ask for 1) More of this item with: MOR, 2) the NEXt section with: NEX, or 3) a different item by it's handle (ex. C3, S2) (only 3 chars don't summarize yet)

ATAI_OUT_5 [2025-04-02 17:43:37 -0400] 924 Bytes | 265 tokens | Cum: 1507 tkns (18.84% of 8k)
==========================================================================

We present this news so you can catch the big movers from recently breaking news.
Here's a list of news articles you can literally read just by asking.
Usually the first item is the most important.

A1 - 2025-03-29T13:28:00Z - atai Life Sciences CEO discusses major data readouts expected through 2025 - ICYMI...
A2 - 2025-03-26T12:40:53Z - insiders make huge purchases of these 4 biotech stocks...
A3 - 2025-03-25T01:02:07Z - Atai Life Sciences CEO Rao Srinivas sells $101,814 in common shares By Investing.com...
A4 - 2025-03-25T01:02:08Z - Atai Life Sciences chief scientific officer sells $17,767 in shares By Investing.com...
A5 - 2025-03-25T01:04:05Z - Atai Life Sciences chief business officer sells $65,560 in stock By Investing.com...

Request an article by its reference number. (Ex., "A1" gets the first item)
You may also say NEX to go to the next listing.
Response to this prompt limited to 3 chars.

ATAI_OUT_7 [2025-04-02 17:43:40 -0400] 1098 Bytes | 315 tokens | Cum: 1824 tkns (22.80% of 8k)
==========================================================================

Showing A1 (chunk 1 of 5): A1:
**atai Life Sciences CEO discusses major data readouts expected through 2025 - ICYMI**Date: 2025-03-29Source: {'uri': 'proactiveinvestors.com', 'dataType': 'news', 'title': 'Proactiveinvestors NA'}URL: https://www.proactiveinvestors.com/companies/news/1068767/atai-life-sciences-ceo-discusses-major-data-readouts-expected-through-2025-icymi-1068767.htmlatai Life Sciences (NASDAQ:ATAI, ETR:9VC) CEO Dr Srinivas Rao talked with Proactive about the company's upcoming clinical milestones and strategic focus in 2025.

Rao outlined four major clinical readouts across atai's pipeline of short-duration psychedelics, including updates on VLS-01, BPL-003, RL-007 and EMP-01.

Proactive: Hello you're watching Proactive. Joining me is atai Life Sciences CEO and co-founder, Dr Srinivas Rao. Srinivas, very good to speak with you. There's lots of exciting updates announced as a part of your year-end re

--> You can ask for 1) More of this item with: MOR, 2) the NEXt section with: NEX, or 3) a different item by it's handle (ex. C3, S2) (only 3 chars don't summarize yet)

ATAI_OUT_9 [2025-04-02 17:43:41 -0400] 1114 Bytes | 331 tokens | Cum: 2217 tkns (27.71% of 8k)
==========================================================================

This is our final list of news.
News AI can literally read just by asking.
Don't miss the breaking news!

B1 - 2025-02-25T18:00:00Z - Comprehensive Market Analysis of Latest Published Different Types of Depression Reports | DelveInsight
B2 - 2025-02-13T03:47:00Z - atai Life Sciences Announces Pricing of Public Offering of Common Shares
B3 - 2025-01-22T18:00:00Z - 5-HT2 Agonist Clinical Trial Pipeline Appears Robust With 20+ Key Pharma Companies Actively Working in the Therapeutics Segment | DelveInsight
B4 - 2024-08-06T19:13:00Z - 4 Psychedelic Stocks to Consider as Clinical Trials Heat up
B5 - 2024-06-26T11:00:00Z - atai Life Sciences to Participate in the H.C. Wainwright 5th Annual Neuro Perspectives Conference
B6 - 2024-06-20T11:00:00Z - atai Life Sciences Announces Update on Beckley Psytech’s Phase 1/2a Trial of ELE-101 (IV Psilocin) for Major Depressive Disorder, with Initial Results from Phase 1 and First Patients Dosed in Phase 2a

Request an article by its reference number. (Ex., "B1" gets the first item)
You can say NEX to go to the next listing.
Response limited to 3 chars.

ATAI_OUT_11 [2025-04-02 17:43:43 -0400] 823 Bytes | 215 tokens | Cum: 2434 tkns (30.43% of 8k)
==========================================================================

Showing B2 (chunk 1 of 1): B2:
**atai Life Sciences Announces Pricing of Public Offering of Common Shares**Date: Unknown DateSource: Unknown SourceURL: https://www.globenewswire.com/news-release/2025/02/13/3025562/0/en/atai-Life-Sciences-Announces-Pricing-of-Public-Offering-of-Common-Shares.htmlatai Life Sciences, a clinical-stage biopharmaceutical company, announced the pricing of a registered underwritten offering of 26,190,477 common shares at $2.10 per share, raising approximately $55 million. The company intends to use the net proceeds for general corporate purposes, including advancing the clinical development of its product candidates.

--> You can ask for 1) More of this item with: MOR, 2) the NEXt section with: NEX, or 3) a different item by it's handle (ex. C3, S2) (only 3 chars don't summarize yet)

ATAI_OUT_13 [2025-04-02 17:43:44 -0400] 535 Bytes | 136 tokens | Cum: 2644 tkns (33.05% of 8k)
==========================================================================

This is our list of SEC filings.
If empty, the search returned no recent filings.

S7 - 2025-03-20 8-K Item 7.01. Regulation FD Disclosure .

On March 20, 2025, atai Life Sciences N.V. (the Company) announced that it has decided to add Bitcoin to its treasury reserve diversification strategy in addition to cash, restricted cash, cash equiv, short-term securities, and public...

Request filing by its reference number. (Ex., "S1" gets the first item)
You can say NEX to go to the next listing.
Response limited to 3 chars.

ATAI_OUT_15 [2025-04-02 17:43:50 -0400] 1098 Bytes | 257 tokens | Cum: 2903 tkns (36.29% of 8k)
==========================================================================

Showing S7 (chunk 1 of 4): S7:
Item 7.01. Regulation FD Disclosure .

On March 20, 2025, atai Life Sciences N.V. (the Company) announced that it has decided to add Bitcoin to its treasury reserve diversification strategy in addition to cash, restricted cash, cash equivalents, short-term securities, and public equity holdings. Over the next several weeks, the Company expects to invest an initial position of $5.0 million in Bitcoin to hold as a treasury reserve asset. The Bitcoin treasury reserve is not anticipated to impact drug development timelines or current operational runway.

The information contained in Item 7.01 of this Current Report shall not be deemed filed for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the Exchange Act), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933

--> You can ask for 1) More of this item with: MOR, 2) the NEXt section with: NEX, or 3) a different item by it's handle (ex. C3, S2) (only 3 chars don't summarize yet)

ATAI_OUT_17 [2025-04-02 17:43:59 -0400] 5727 Bytes | 1701 tokens | Cum: 4682 tkns (58.53% of 8k)
==========================================================================

This is our set of metrics.
Please analyze the numbers.

+-------------------+-----------------------+-------------------------+--------------------------+
| Volume: 2,592,455 | Perf Month: -4.82% | Option/Short: Yes / Yes | Sales Y/Y TTM: -0.90% |
+-------------------+-----------------------+-------------------------+--------------------------+
| Avg Volume: 2.88M | Perf Quarter: 9.63% | Short Float: 7.70% | ROE: -62.43% |
+-------------------+-----------------------+-------------------------+--------------------------+
| Rel Volume: 0.90 | Index: - | Short Ratio: 3.61 | ROI: -77.07% |
+-------------------+-----------------------+-------------------------+--------------------------+
| RSI (14): 48.15 | Market Cap: 293.49M | Short Interest: 10.40M | Sales Surprise: -101.67% |
+-------------------+-----------------------+-------------------------+--------------------------+
| ATR (14): 0.15 | Shs Outstand: 167.82M | Beta: 1.25 | EPS Surprise: -51.32% |
+-------------------+-----------------------+-------------------------+--------------------------+
| SMA20: 2.14% | Shs Float: 135.18M | Sales Q/Q: -54.02% | P/E: - |
+-------------------+-----------------------+-------------------------+--------------------------+
| SMA50: -13.03% | Inst Own: 7.34% | Sales past 5Y: -13.20% | Earnings: Mar 17 BMO |
+-------------------+-----------------------+-------------------------+--------------------------+
| SMA200: 3.02% | Insider Own: 31.83% | Employees: 54 | |
+-------------------+-----------------------+-------------------------+--------------------------+
| Perf Week: 0.68% | Insider Trans: 24.58% | Debt/Eq: 0.16 | |
+-------------------+-----------------------+-------------------------+--------------------------+

The next section covers any insider trading.
If this section may be blank due to no recent filings.

Inside Trans: ATAI Life Sciences N.V. (ATAI) by Kirpekar Sahil (Chief Business Officer) on 2025-03-21
- Common Shares: 48563 shares at $1.35 (D)

Inside Trans: ATAI Life Sciences N.V. (ATAI) by Craig Kevin James (Chief Medical Officer) on 2025-03-21
- Common Shares: 11563 shares at $1.35 (D)

Inside Trans: ATAI Life Sciences N.V. (ATAI) by Rao Srinivas (See Remarks) on 2025-03-21
- Common Shares: 75418 shares at $1.35 (D)

Inside Trans: ATAI Life Sciences N.V. (ATAI) by Johnson Anne Nagengast (Chief Financial Officer) on 2025-03-21
- Common Shares: 33545 shares at $1.35 (D)

Inside Trans: ATAI Life Sciences N.V. (ATAI) by Short Glenn Frank (Chief Scientific Officer) on 2025-03-21
- Common Shares: 13161 shares at $1.35 (D)

Inside Trans: ATAI Life Sciences N.V. (ATAI) by Apeiron Investment Group Ltd. (Unknown Title) on 2025-03-24
- Common Shares: 1800000 shares at $1.4 (I)

Inside Trans: ATAI Life Sciences N.V. (ATAI) by Kirpekar Sahil (Chief Business Officer) on 2025-03-14
- Common Shares: 100000 shares at $N/A (D)
- Common Shares: 100000 shares at $N/A (D)

Inside Trans: ATAI Life Sciences N.V. (ATAI) by Craig Kevin James (Chief Medical Officer) on 2025-03-14
- Common Shares: 20000 shares at $N/A (D)
- Restricted Stock Units: 20000 shares at $0 (D)

Inside Trans: ATAI Life Sciences N.V. (ATAI) by Short Glenn Frank (Chief Scientific Officer) on 2025-03-14
- Common Shares: 32500 shares at $N/A (D)
- Restricted Stock Units: 32500 shares at $0 (D)

[Company Financial Summary]
[Company Details]
Name: N/A
Market Cap: N/A
Shares Outstanding: N/A
Sector: N/A

[Financial Statements - Latest Quarter]
Total Assets: N/A
Total Liabilities: N/A
Total Equity: N/A
Revenue (Quarter): {'value': 308000, 'unit': 'USD', 'label': 'Revenues', 'order': 100}
Net Income: {'value': -150049000.0, 'unit': 'USD', 'label': 'Net Income/Loss', 'order': 3200}
Earnings Per Share (EPS): N/A

[Price Metrics - Last 30 Days]
Latest Close: 1.48
Average Volume: 1873045.52
30-Day High: 1.61
30-Day Low: 1.24

[Detailed Financials: TTM 2024]
- Total Assets: $159,387,000.0
- Total Liabilities: $42,833,000.0
- Total Equity: $116,554,000.0
- Current Assets: $80,125,000.0
- Current Liabilities: $24,951,000.0

[Income Statement: TTM 2024]
- Revenue: $308,000.00
- Net Income: N/A
- Gross Profit: N/A
- Operating Income: N/A
- Earnings Per Share (EPS): -0.93

[Cash Flow Statement: TTM 2024]
- Net Cash Flow: $-17,891,000.0

[Detailed Financials: FY 2024]
- Total Assets: $159,387,000.0
- Total Liabilities: $42,833,000.0
- Total Equity: $116,554,000.0
- Current Assets: $80,125,000.0
- Current Liabilities: $24,951,000.0

[Income Statement: FY 2024]
- Revenue: $308,000.00
- Net Income: N/A
- Gross Profit: N/A
- Operating Income: N/A
- Earnings Per Share (EPS): -0.93

[Cash Flow Statement: FY 2024]
- Net Cash Flow: $-17,891,000.0
==== END OF FINANCIAL REPORT ====

You are now requested to make a summary analysis.
Save explaining why you didn't have enough information for the final survey.

Now, complete this report with the following:

1) Brief Summary: explain your findings in succinct wording.
2) MARKET_SCORE: If you calculate a 92% likelihood of an upward moves, say: MARKET_SCORE[92]
3) PRICE_TARGET: If you think the high today will be 50% higher, add to the price.
Eg., If the current price is $5.00, add 50%. Thus, PRICE_TARGET[$7.50] -- It should be at or above the current price.
4) Provide a thought-provoking take, 6-10 words, to use for the headline of this news story.
Like this: AI_RPT_HEADLINE: [6-12 words headline for news story, distilled from summary]

1) Brief Summary, 2) MARKET_SCORE, 3) PRICE_TARGET, and 4) AI_RPT_HEADLINE

ATAI_OUT_19 [2025-04-02 17:44:01 -0400] 676 Bytes | 167 tokens | Cum: 5081 tkns (63.51% of 8k)
==========================================================================

Finally, if more data could have improved your confidence which would you have chosen? **Choose one option:**
-> X0 <- Nothing more would have helped my analysis
-> X1 <- More stock-specific news
-> X2 <- More SEC filings (10-K, 10-Q, 8-K) Financials, risk disclosures, and business changes
-> X3 <- More SEC Insider Trading (Form 3, 4, 5) Direct buys/sells from executives and institutions
-> X4 <- Broader sector & market news
-> X5 <- Your past analysis on similar companies (specify metrics)
-> X6 <- More financial metrics
-> X7 <- Your past analysis on this exact company
-> X8 <- Something altogether different (explain...)

ATAI_IN_21 [2025-04-02 17:44:02 -0400] 126 Bytes | 29 tokens | Cum: 5171 tkns (64.64% of 8k)
==========================================================================

====================================
[2025-04-02 17:44:02] # Analysis Completed
Elapsed Time: 32.65 seconds